To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia: A randomized study by the Swedish CLL group
Uppsala Univ, Dept Med Sci, Sect Hematol, Uppsala, Sweden.
Orebro Univ Hosp, Dept Med, Sect Hematol, Orebro, Sweden.
Falun Cent Hosp, Dept Med, Falun, Sweden.
Lund Univ Hosp, Fac Med, Inst Clin Sci, Lund, Sweden.
Show others and affiliations
2018 (English)In: Vaccine, ISSN 0264-410X, E-ISSN 1873-2518, Vol. 36, no 25, p. 3701-3707Article in journal (Refereed) Published
Abstract [en]

Aim: To determine if patients with untreated chronic lymphocytic leukemia (CLL) benefit from vaccination with a 13-valent pneumococcal conjugated vaccine (PCV13), Prevenar13 (R), compared to a 23-valent pneumococcal polysaccharide vaccine (PPSV23), Pneumovax (R), in terms of immune response.

Background: Streptococcus pneumoniae causes substantial morbidity in patients with CLL, a group known to respond poorly to polysaccharide vaccines. Comparative studies with conjugated vaccines are lacking.

Methods: 128 treatment naive CLL patients from eight hematology clinics in Sweden were randomized to vaccination with PCV13 (n = 63) or PPSV23 (n = 65) after stratification by IgG level and CLL clinical stage (Rai). Blood samples for evaluation of immune response were obtained at baseline, and at one and six months after vaccination. Analyses for each of the 12 pneumococcal serotypes common for PCV13 and PPSV23 were performed by opsonophagocytic assay (OPA) and enzyme-linked immunosorbent assay (ELISA).

Results: PCV13 elicited a superior immune response than PPSV23 in 10/12 serotypes one month after vaccination and in 5/12 serotypes six months after vaccination, measured as OPA geometric mean titers (GMTs). Geometric mean concentrations of serotype-specific IgG antibodies elicited by PCV13 as measured by ELISA, were higher than those elicited by PPSV23 in half of the common serotypes, both after one and six months. PPSV23 did not trigger a better immune response than PCV13 for any of the serotypes, regardless of analysis method or time point of analysis. Negative predictive factors for vaccination response were hypogammaglobulinemia and long disease duration. Both vaccines were well tolerated.

Conclusions: In patients with previously untreated CLL, the efficacy of PCV13 in terms of immune response is superior to PPSV23 for most serotypes common for the two vaccines. We therefore propose that PCV13 should be included in vaccination programs against Streptococcus pneumoniae for CLL patients and administered as early as possible during the course of the disease.

Place, publisher, year, edition, pages
Elsevier, 2018. Vol. 36, no 25, p. 3701-3707
Keywords [en]
Chronic lymphocytic leukemia (CLL), Pneumococcal vaccine, Polysaccharide vaccine, Protein-conjugate vaccine, Immunogenicity
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:oru:diva-120747DOI: 10.1016/j.vaccine.2018.05.012ISI: 000436202800022PubMedID: 29748028OAI: oai:DiVA.org:oru-120747DiVA, id: diva2:1954327
Funder
Region StockholmRegion Uppsala
Note

The study was funded by governmental research funds from the Stockholm county council, Uppsala county council and supported by the national Swedish CLL-group. This study was also supported by funding and study drug (Prevenar) supply by Pfizer. Serological analyses were performed at Pfizer’s Vaccine Research Clinical Testing laboratory in US. Statistical analyses were performed by Statisticon, Uppsala.

Available from: 2025-04-24 Created: 2025-04-24 Last updated: 2025-04-28Bibliographically approved
In thesis
1. Immune response to pneumococcal vaccination in chronic lymphocytic leukemia
Open this publication in new window or tab >>Immune response to pneumococcal vaccination in chronic lymphocytic leukemia
2025 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Patients with chronic lymphocytic leukemia (CLL) are at increased risk of Streptococcus pneumoniae infections due to disease- and treatment-related immune dysfunction. Vaccine responses are often impaired. This thesis evaluates the immune response to primary immunization with pneumococcal conjugate vaccine (PCV) versus pneumococcal polysaccharide vaccine (PPSV), long-term antibody persistence and the effect of revaccination in CLL patients.

Study I was a randomized trial in treatment-naïve CLL patients comparing PCV and PPSV, demonstrating that PCV elicits an enhanced immune response.

Study II was a prospective study evaluating B-cell subsets and plasmablast dynamics before and after revaccination. It showed that repeated revaccinations with PCV in CLL patients improves early humoral response.

Study III assessed antibody persistence 5 years after primary immunization and response to revaccination, showing that CLL patients have poor long-term antibody persistence, but that revaccination with PCV enhances immunity.

Study IV examined the impact of two analytical methods, multiplex immunoassay (MIA) and enzyme immunoassay (EIA), on serotypespecific IgG measurements and demonstrated their influence on vac-cine response interpretation in CLL patients. The findings in this thesis emphasize the importance of pneumococcal conjugate vaccines in CLL patients and suggest a need for revaccination to maintain protection against severe pneumococcal disease.

Place, publisher, year, edition, pages
Örebro: Örebro University, 2025. p. 105
Series
Örebro Studies in Medicine, ISSN 1652-4063 ; 320
Keywords
chronic lymphocytic leukemia, secondary immunodefi-ciency, vaccine response, pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, pneumococcal revaccination
National Category
General Medicine
Identifiers
urn:nbn:se:oru:diva-119411 (URN)9789175296470 (ISBN)9789175296487 (ISBN)
Public defence
2025-05-16, Örebro universitet, Campus USÖ, Tidefeltsalen, Södra Grev Rosengatan 32, Örebro, 09:00 (Swedish)
Opponent
Supervisors
Available from: 2025-02-26 Created: 2025-02-26 Last updated: 2025-05-16Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records

Kättström, Magdalena

Search in DiVA

By author/editor
Kättström, MagdalenaCherif, HonarKimby, Eva
In the same journal
Vaccine
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 4 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf